Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Multiple Sclerosis Health Center

Font Size

Novantrone Helps Worsening MS

Drug Already Available in U.S.
WebMD Health News

Dec. 27, 2002 -- Novantrone slows worsening multiple sclerosis (MS), a European study shows. Based largely on these results, the drug already has U.S. FDA approval.

Novantrone apparently inhibits the nerve-destroying immune responses at the heart of MS. It's the only drug now approved for treatment of worsening relapsing-remitting, progressive relapsing, and secondary progressive MS. The FDA approved the cancer drug for treatment in MS patients in 2000.

"We believe [Novantrone] provides a new therapeutic option," write study leader Hans-Peter Hartung, MD, Heinrich-Heine University, Düsseldorf, Germany, and colleagues.

Hartung's team enrolled 188 patients with worsening MS. A third got a placebo, another third got a low dose of Novantrone, and the final third got a higher dose of the drug. Those who received the higher dose (the FDA-approved 12 mg per square meter of body surface once every three months for 24 months) did best. On an index of five measures of MS disease -- disability status, ability to walk, number of treated relapses, time to first treated relapse, and change in neurological status -- they did 70% better than placebo-treated patients.

The drug was well tolerated. The most serious side effect of Novantrone treatment can be congestive heart failure. This is seen in up to 6% leukemia patients who, over time, accumulate a total dose of up to 140 mg per square meter of body surface. In the current study of MS patients, there were no serious heart problems. However, a few patients with previous heart problems had worsening of heart function.

The study was sponsored by Wyeth-Lederle, Novantrone's manufacturer.

Hartung and colleagues plan further studies to find out which MS patients are most likely to respond to treatment and how best to use Novantrone. They're also looking carefully for long-term side effects.

Today on WebMD

nerve damage
Learn how this disease affects the nervous system.
woman applying lotion
Ideas on how to boost your mood and self-esteem.
woman pondering
Get personalized treatment options.
man with hand over eye
Be on the lookout for these symptoms.
brain scan
worried woman
neural fiber
white blood cells
sunlight in hands
marijuana plant
muscle spasm